Huadong Ebitda from 2010 to 2024

000963 Stock   35.95  0.24  0.66%   
Huadong Medicine's EBITDA is increasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about 3.9 B. From 2010 to 2024 Huadong Medicine EBITDA quarterly data regression line had arithmetic mean of  3,219,603,147 and r-squared of  0.76. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
4.4 B
Current Value
3.9 B
Quarterly Volatility
653.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Huadong Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Huadong Medicine's main balance sheet or income statement drivers, such as Interest Expense of 120.7 M, Selling General Administrative of 2.8 B or Total Revenue of 42.7 B, as well as many indicators such as . Huadong financial statements analysis is a perfect complement when working with Huadong Medicine Valuation or Volatility modules.
  
This module can also supplement various Huadong Medicine Technical models . Check out the analysis of Huadong Medicine Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Huadong Stock

Huadong Medicine financial ratios help investors to determine whether Huadong Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Huadong with respect to the benefits of owning Huadong Medicine security.